4.7 Article

High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 480, Issue 1-2, Pages 137-142

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2015.01.025

Keywords

Electrospinning; Itraconazole; Amorphous solid dispersion; Scaling-up; Dissolution enhancement; Continuous nanoformulation

Funding

  1. New Szechenyi Development Plan [TAMOP-4.2.1/B-09/1/KMR-2010-0002]
  2. OTKA research fund [K112644, PD108975]
  3. MedInProt Synergy Program
  4. Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences

Ask authors/readers for more resources

High speed electrospinning (HSES), compatible with pharmaceutical industry, was used to demonstrate the viability of the preparation of drug-loaded polymer nanofibers with radically higher productivity than the known single-needle electrospinning (SNES) setup. Poorly water-soluble itraconazole (ITRA) was formulated with PVPVA64 matrix polymer using four different solvent- based methods such as HSES, SNES, spray drying (SD) and film casting (FC). The formulationswere assessed in terms of improvement in the dissolution rate of ITRA (using a tapped basket dissolution configuration) and analysed by SEM, DSC and XRPD. Despite the significantly increased productivity of HSES, the obtained morphology was very similar to the SNES nanofibrous material. ITRA transformed into an amorphous form, according to the DSC and XRPD results, in most cases except the FC samples. The limited dissolution of crystalline ITRA could be highly improved: fast dissolution occurred (>90% within 10 min) in the cases of both (the scaledup and the single-needle) types of electrospun fibers, while the improvement in the dissolution rate of the spray-dried microspheres was significantly lower. Production of amorphous solid dispersions (ASDs) with the HSES system proved to be flexibly scalable and easy to integrate into a continuous pharmaceutical manufacturing line, which opens new routes for the development of industrially relevant nanopharmaceuticals. (C) 2015 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available